Physician profile
Michael Darwin Killpack
NPI 1588714091
$1,667.26
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $873 · 2020: $552 · 2021: $228 · 2022: $14.24.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $183.97 | 2019-2020 | |
| Astellas Pharma US INC | $166.92 | 2019-2021 | |
| Amgen INC. | $158.49 | 2019-2020 | |
| Amarin Pharma, INC. | $130.92 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $118.38 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $117.68 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $103.71 | 2019-2020 | |
| Alkermes, INC. | $87.29 | 2019-2020 | |
| Pfizer INC. | $79.09 | 2019-2020 | |
| Novo Nordisk INC | $77.84 | 2019-2020 | |
| Abbvie INC. | $77.50 | 2019-2022 | |
| Glaxosmithkline, LLC. | $40.17 | 2020-2021 | |
| Gilead Sciences, INC. | $31.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.85 | 2019-2021 | |
| Sanofi Pasteur INC. | $31.27 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.10 | 2019 | |
| Boston Scientific Corporation | $22.18 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.77 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $19.69 | 2019 | |
| Acadia Pharmaceuticals INC | $17.35 | 2019 | |
| Seqirus USA INC | $16.68 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.64 | 2019 | |
| Insmed, INC. | $16.37 | 2020 | |
| Mannkind Corporation | $14.70 | 2020 | |
| Medtronic Minimed, INC. | $13.35 | 2020 | |
| Eisai INC. | $12.94 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.87 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.40 | 2021 | |
| Lilly USA, LLC | $11.21 | 2019 |
10 companies reported research payments only; those appear in the research section below.
Research and ownership
$5,403.34 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Killpack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.